Cronos Group Stock News

CRON earnings call for the period ending December 31, 2021.

CRON earnings call for the period ending December 31, 2021.

Canadian cannabis player, Cronos Group (CRON) posted a mixed performance with its Q4 2021 financials on Tuesday as earnings fell short of the consensus despite a revenue beat.In…

Cronos Group Inc. (CRON) CEO Kurt Schmidt on Q4 2021 Results - Earnings Call Transcript

Cronos Group Inc. (NASDAQ: CRON ) (TSX: CRON) announced its 2021 fourth quarter and full-year business and financial results. "Our fourth quarter 2021 results indicate positive momentum, which we will look to carry forward as we begin to implement our strategic and operational realignment initiatives,” Kurt Schmidt, president and CEO of Cronos Group, said. “As we look to 2022, we will continue to realign Cronos Group''s organizational structure to match our strategy, with a primary focus on adult-use products and elevating our brands through rare cannabinoids.” Fourth Quarter 2021 Financial Highlights Net revenue of $25.8 million increased by $8.7 million from the prior year''s period. The increase year-over-year was primarily driven by continued growth in the adult-use market in Canada and increased sales in the Israeli medical market. Gross profit of $1.9 million improved by $16.8 million year-over-year. The improvement year-over-year was primarily driven by increased gross profit in the Rest of World segment as well as a decline in inventory write-downs.

Cronos Group said Tuesday its fourth-quarter loss increased to $133.89 million, or 36 cents a share, from $111.71 million, or 31 cents a share, in the year-ago quarter. Net revenue increased to $25.8 million from $17.05 million. Cronos booked a $119.9 million impairment charge in the latest quarter as a result of plan to exit its Peace Naturals Campus. Analysts expected a loss of 11 cents a share on revenue of $23.9 million, according to a survey by FactSet. "Our fourth quarter 2021 results indicate positive momentum, which we will look to carry forward as we begin to implement our strategic and operational realignment initiatives," CEO Kurt Schmidt said in a statement. Shares of Cronos group fell 4.8% in premarket trades. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

https://www.investing.com/analysis/cronos-group-still-struggles-as-grower-awaits-us-cannabis-legalization-200618974

Cronos Group press release (CRON): Q4 GAAP EPS of -$0.36 misses by $0.25.Revenue of $25.8M (+51.3% Y/Y) beats by $1.94M.Shares -0.56% PM.

Consolidated net revenue increased 59% in Full Year 2021 compared to Full Year 2020

Consolidated net revenue increased 59% in Full Year 2021 compared to Full Year 2020

You don't need a lot of money to enjoy fantastic returns with this trio of stocks.

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Pieris Pharmaceuticals Inc (NASDAQ: PIRS ), Baidu Inc (NASDAQ: BIDU ) and Cronos Group Inc (NASDAQ: CRON ): Traders and investors will be watching for Pieris’s fourth-quarter earnings report, confirmed for Tuesday’s pre-market session. According to analyst consensus estimates, Pieris is expected to report an EPS loss of 3 cents on revenue of $2.45 million. Pieris reported in November an EPS loss of … Full story available on Benzinga.com

Cronos Group (NASDAQ:CRON) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate…